Presidio Medical is a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform with a first indication in the treatment of chronic pain. The technology leverages scientific principles discovered by Hodgkin and Huxley and aims to inhibit undesirable nerve activity rather than using short-pulse excitation. Early research in animals, computational modeling, and humans was published in Science Translational Medicine in 2021. Presidio's ULF therapy has been trialed in over 50 patients for 15 days each, with patients reporting greater than 90% pain relief on average. The company plans to use new funding to expand the team, scale manufacturing, and conduct long-term pivotal clinical studies to demonstrate durability and potency. Presidio was founded in 2017 and is headquartered in South San Francisco, California. Presidio Medical is a clinical-stage, privately-held medical device company developing a neuromodulation technology platform with a first indication in the treatment of chronic pain. Its technology is designed to provide pain relief across a broad spectrum of pain types where conventional treatment has failed. The company was founded in 2017 and is headquartered in South San Francisco. The announced financing will be used to further develop the current technology for treatment of chronic pain and to expand application of the platform to additional indications. Presidio targets patients who fail or receive minimal relief from standard pain treatments, an important unmet medical need.

Total raised

$102M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2023